Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model

Ophthalmic Research

Volumn 48, Issue 3, 2012, Pages 118-123

  Öner, Veysi ^a   Küçükerdönmez, Cem ^a   Akova, Yonca Aydn ^a   Çolak, Aysel ^a   Karalezli, Aylin ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Corneal neovascularization; VEGF

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIGITAL IMAGING; DRUG EFFICACY; HISTOPATHOLOGY; IMAGE ANALYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAOCULAR; MALE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860186520     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000337139     Document Type: Article

References (32)

1. Lee P, Wang CC, Adamis AP: Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998; 43: 245-269. (Pubitemid 28558273)
2. Cursiefen C, Küchle M, Naumann GO: Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998; 17: 611-613. (Pubitemid 28511907)
3. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P: Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007; 26: 977-982. (Pubitemid 47329805)
4. Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol 2001; 12: 242-249. (Pubitemid 32751680)
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400. (Pubitemid 38618122)
6. Hashemian MN, Z-Mehrjardi H, Moghimi S, Tahvildari M, Mojazi-Amiri H: Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Ophthalmic Res 2011; 46: 50-54.
7. Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alió JL: Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010; 150: 519-528.
8. Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M: The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 2010; 88: 862-867.
9. Gueudry J, Richez F, Tougeron-Brousseau B, Genevois O, Muraine M: Subconjunctival bevacizumab for corneal neovascularization (in French). J Fr Ophtalmol 2010; 33: 630-636.
10. You IC, Kang IS, Lee SH, Yoon KC: Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2009; 87: 653-658.
11. Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH: Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008; 27: 357-362. (Pubitemid 351440874)
12. Kim WJ, Jeong HO, Chung SK: The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol 2010; 24: 230-236.
13. Ahmed A, Berati H, Nalan A, Aylin S: Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Experiment Ophthalmol 2009; 37: 730-736.
14. Mahoney JM, Waterbury LD: Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985; 4: 531-535. (Pubitemid 15066517)
15. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P: Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007; 91: 804-807. (Pubitemid 46846656)
16. Phillips K, Arffa R, Cintron C, Rose J, Miller D, Kublin CL, Kenyon KR: Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 1983; 101: 640-643. (Pubitemid 13116481)
17. Joussen AM, Kruse FE, Volcker HE, Kirchhof B: Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 1999; 237: 920-927. (Pubitemid 29484167)
18. Murata M, Shimizu S, Horiuchi S, Taira M: Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2006; 244: 205-209.
19. Harvey PT, Cherry PM: Indometasin and dexamethasone in the suppression of corneal neovascularization. Can J Ophtalmol 1983; 18: 293-295. (Pubitemid 14230611)
20. Haynes WL, Proia Ad, Klintworth GK: Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophtalmol Vis Sci 1989; 30: 1588-1593. (Pubitemid 19185963)
21. Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP: Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002; 120: 1063-1068. (Pubitemid 34856074)
22. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113: 2002.
23. Bashshur ZF, Bazarbachi A, Shakal A, Haddad ZA, El Haibi CP, Noureddin BN: Intravitreal bevacizumab for the management of choroidal neovascularization in age related macular degeneration. Am J Ophtalmol 2006; 142: 1-9. (Pubitemid 43946791)
24. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Ophtalmology 2006; 113: 363-372.
25. Avery RL: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352-354. (Pubitemid 44318195)
26. Spaide RF, Fisher YL: Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-278. (Pubitemid 44318179)
27. Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R: Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011; 52: 8718-8723.
28. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C: Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545-2552. (Pubitemid 351261204)
29. Rocher N, Behar-Cohen F, Pournaras JA, Naud MC, Jeanny JC, Jonet L, Bourges JL: Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. Mol Vis 2011; 17: 104-112.
30. Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR: Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009; 50: 1659-1665.
31. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R: Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127: 381-389.
32. Erdurmus M, Totan Y: Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1577-1579. (Pubitemid 47423342)